Oragenics Secures Key Regulatory Approval for Phase IIa Clinical Trial of ONP-002 for Concussion and mTBI in Australia

Key Highlights

• Human Research Ethics Committee (HREC) Approval: Oragenics has received final HREC approval in Australia to initiate its Phase IIa clinical trial for ONP-002, a novel treatment for concussion and mild traumatic brain injury (mTBI).
• All Regulatory Approvals Secured: The company has obtained all necessary regulatory clearances to begin onboarding clinical sites and enrolling patients at three locations in Australia, with Bayside Health (Alfred Health) as the lead site.
• Potential First-in-Class Therapy: If approved, ONP-002 could become the first and only FDA-approved pharmacological treatment for concussion/mTBI, addressing a significant unmet medical need.
• Significant Market Opportunity: The global concussion market is projected to surpass \$9 billion by 2030, while the nasal drug delivery market may reach nearly \$93 billion by the same year.
• Phase IIa Trial Design: The trial is a randomized, placebo-controlled study of 40 patients, with dosing expected within 12 hours of injury and continued treatment for up to 30 days.
• Imminent Clinical Milestone: Patient dosing is expected to begin before the end of March 2026, with Phase IIa data readout anticipated before year-end 2026.
• Planned U.S. Expansion: Positive results would support an IND submission to the FDA, paving the way for U.S.-based clinical trials.

Detailed Article

Sarasota, FL – March 10, 2026: Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company specializing in brain-targeted therapeutics via proprietary intranasal delivery technology, announced a major milestone with the receipt of final Human Research Ethics Committee (HREC) approval to commence its Phase IIa clinical trial for the lead drug candidate, ONP-002, in Australia.

Why This Matters

Concussion and mTBI are among the most prevalent neurological conditions, yet there are currently no FDA-approved pharmacological treatments. According to the CDC, an estimated 1.7 to 3.8 million people in the U.S. suffer traumatic brain injuries annually, with sports and recreational activities being leading causes. Globally, approximately 69 million people sustain TBIs each year. The absence of effective treatment options leaves millions, including patients, athletes, military personnel, and families, with only rest and symptom management as interventions.

ONP-002 is positioned as a potential breakthrough: it is the first-in-class intranasal neurosteroid designed not just to manage symptoms, but to address the underlying biology of mTBI by reducing neuroinflammation, oxidative stress, and cerebral edema. This approach could transform the standard of care from passive symptom control to active neurological intervention.

Clinical and Market Significance

• The company has completed all regulatory filings and secured approval for onboarding three clinical sites, with Bayside Health (Alfred Health) as the lead site.
• The Phase IIa trial will enroll 40 patients who meet eligibility based on CT scan findings, symptoms, and hospital admission status. Dosing will begin within 12 hours of injury, followed by up to 30 days of treatment and comprehensive safety and efficacy follow-up, including neurocognitive testing and nasal examinations.
• The study is designed to evaluate safety, tolerability, and feasibility, with the goal of generating data to support a future IND application with the FDA for U.S. clinical development.
• Oragenics expects to dose the first patient before March-end 2026, with data readout anticipated by year-end 2026.

Management Commentary

“Concussion and mTBI represent areas of enormous unmet medical need, and we have spent years building toward this moment responsibly and rigorously. With our Australian HREC and governance approvals now in place, we have everything we need to move forward expeditiously with clinical site onboarding and patient enrollment in Australia. We expect to dose our first patient before the end of March. This is a major milestone for Oragenics – but more importantly, it is a meaningful step toward bringing a potential breakthrough therapy to a patient population that has had no viable treatment options.”
– Janet Huffman, Chief Executive Officer, Oragenics

“The HREC approval process is thorough by design – it exists to protect patients and ensure that only protocols with sound scientific rationale and rigorous safeguards move forward. As a clinician who has worked with concussion patients for decades, I understand the significance of this moment. ONP-002 targets the injury itself, not just the symptoms. That is a fundamentally different approach to mTBI care, and we are now putting it to the test in patients. The Phase 1 safety profile gives us strong confidence as we advance into this next phase.”
– Dr. James Kelly, Chief Medical Officer, Oragenics

Supporting Evidence

• Phase 1 Data: ONP-002 showed a strong safety profile with zero serious adverse events across all dose levels.
• Preclinical Evidence: Demonstrated reductions in brain swelling, inflammation, oxidative stress, and improvements in functional recovery.
• Trial Management: Southern Star Research, a leading Australian CRO, will oversee all aspects of the Phase IIa trial.

About ONP-002

ONP-002 is an investigational, neuroprotective, anti-inflammatory intranasal drug candidate specifically targeting mTBI. It is designed to rapidly deliver the drug to the brain, potentially interrupting key biological pathways involved in inflammation and swelling following head trauma. The proprietary intranasal platform could position Oragenics for broader applications, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.

Shareholder Considerations and Potential Price Sensitivity

• First-in-Class Potential: Success in this trial would establish ONP-002 as the first-ever pharmacological standard of care for concussion/mTBI, a market with no current FDA-approved therapies.
• Market Size and Growth: The target market is significant, with projections over \$9 billion for concussion treatment and nearly \$93 billion for nasal drug delivery by 2030. Positive clinical results could drive substantial upside for Oragenics’ share price.
• Regulatory Pathway: HREC approval de-risks the clinical development process and signals robust trial design and safety standards, which are critical for investor confidence.
• Upcoming Catalysts: First patient dosing in March 2026 and Phase IIa data by the end of 2026 provide clear milestones that may impact share valuation depending on trial outcomes.

About Oragenics, Inc.

Oragenics is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics via proprietary intranasal delivery. The company’s lead candidate, ONP-002, is being soprogressed for mTBI, with U.S. clinical trials planned pending FDA IND approval. Oragenics’ platform may have further neurological applications, and the company is committed to addressing major unmet medical needs in neurological care.

Investor Contact

For further information:
Phone: 800-383-4880
Email: [email protected]

Disclaimer: This article contains forward-looking statements regarding Oragenics’ business, the development and regulatory status of ONP-002, and future prospects. Such statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Investors should review Oragenics’ filings with the SEC and exercise caution before making investment decisions based on this article.

View ORAGENICS INC Historical chart here